Credit Suisse’s Intersect ENT, Inc XENT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
Sell
-77,918
Closed -$2.18M 4600
2022
Q1
$2.18M Sell
77,918
-96,615
-55% -$2.65M ﹤0.01% 2016
2021
Q4
$4.77M Buy
174,533
+64,495
+59% +$1.75M ﹤0.01% 2064
2021
Q3
$2.99M Buy
110,038
+87,669
+392% +$2.17M ﹤0.01% 2497
2021
Q2
$382K Buy
22,369
+2,025
+10% +$37.9K ﹤0.01% 3998
2021
Q1
$425K Sell
20,344
-14,219
-41% -$328K ﹤0.01% 3865
2020
Q4
$791K Buy
34,563
+748
+2% +$14.2K ﹤0.01% 3504
2020
Q3
$551K Sell
33,815
-44,130
-57% -$799K ﹤0.01% 3335
2020
Q2
$1.05M Buy
77,945
+60,301
+342% +$702K ﹤0.01% 2864
2020
Q1
$209K Sell
17,644
-248,607
-93% -$5.51M ﹤0.01% 3625
2019
Q4
$6.63M Buy
266,251
+200,519
+305% +$4.06M ﹤0.01% 1685
2019
Q3
$1.12M Buy
65,732
+38,067
+138% +$693K ﹤0.01% 2935
2019
Q2
$629K Sell
27,665
-1,302
-4% -$35.1K ﹤0.01% 3266
2019
Q1
$933K Buy
28,967
+284
+1% +$8.79K ﹤0.01% 2947
2018
Q4
$808K Buy
28,683
+13,745
+92% +$403K ﹤0.01% 2948
2018
Q3
$429K Sell
14,938
-19,567
-57% -$588K ﹤0.01% 3384
2018
Q2
$1.29M Buy
34,505
+10,579
+44% +$415K ﹤0.01% 2813
2018
Q1
$941K Buy
23,926
+437
+2% +$16K ﹤0.01% 2998
2017
Q4
$761K Sell
23,489
-4,652
-17% -$140K ﹤0.01% 3187
2017
Q3
$878K Buy
28,141
+14,172
+101% +$419K ﹤0.01% 3191
2017
Q2
$391K Buy
+13,969
New +$316K ﹤0.01% 3312
2017
Q1
Sell
-14,297
Closed -$173K 4162
2016
Q4
$173K Sell
14,297
-934
-6% -$12.1K ﹤0.01% 3850
2016
Q3
$241K Sell
15,231
-10,406
-41% -$157K ﹤0.01% 3744
2016
Q2
$332K Buy
+25,637
New +$401K ﹤0.01% 3654
2016
Q1
Sell
-39,173
Closed -$881K 4380
2015
Q4
$881K Sell
39,173
-23,260
-37% -$460K ﹤0.01% 2919
2015
Q3
$1.46M Buy
62,433
+47,741
+325% +$1.32M ﹤0.01% 2499
2015
Q2
$421K Buy
+14,692
New +$385K ﹤0.01% 3830

Credit Suisse's XENT Position: Q2 2022 in Review

Credit Suisse sold out of Intersect ENT, Inc (XENT) in Q2 2022, closing a stake of 77,918 shares — an estimated $2.18M sold.

Credit Suisse first reported a position in XENT in Q2 2015 and held it in 26 quarters. The position peaked at $6.63M in Q4 2019. 0 funds tracked by Wall St. Rank hold XENT as of Q2 2022.

  • Credit Suisse reported no remaining Intersect ENT, Inc position as of Q2 2022 after selling out during the quarter.
  • Credit Suisse sold 77,918 Intersect ENT, Inc shares in Q2 2022, an estimated $2.18M.
  • Credit Suisse first reported a position in Intersect ENT, Inc in Q2 2015 and held it in 26 quarters.
  • Credit Suisse's Intersect ENT, Inc position peaked at $6.63M in Q4 2019.
  • 0 funds tracked by Wall St. Rank held Intersect ENT, Inc as of Q2 2022.

Based on Credit Suisse's 13F filing for Q2 2022, filed 12 Aug 2022.